Novartis Exercises Option to Acquire Sironax Brain Delivery Platform for $125 Million
核心洞察
Novartis exercised its exclusive option to acquire full global rights to Sironax (搜索)'s proprietary brain delivery platform, triggering a $125 million payment to Sironax upon closing.
The platform uses proprietary brain delivery modules designed to transport monoclonal antibodies, peptides, proteins, gene therapies and other large biologics across the blood-brain barrier.
Sironax (搜索) retains rights to develop, manufacture and commercialize selected assets using the platform and will use proceeds to advance three Phase 1b/2 programs.
Novartis has exercised its exclusive option to acquire full global rights to Sironax (搜索)'s proprietary brain delivery platform, following the option and asset purchase agreement announced in July 2025. Under the terms of the option exercise agreement, Sironax will receive $125 million following the closing of the transaction, and the company will retain rights to develop, manufacture, and commercialize selected assets using the platform.
The deal hands a global pharmaceutical leader control of a next-generation brain delivery platform that Sironax (搜索) says has the potential to transform the treatment of central nervous system diseases by overcoming the longstanding challenge of delivering therapeutics across the blood-brain barrier. The platform comprises proprietary brain delivery modules engineered to potentially enable the in vivo transport of diverse therapeutic modalities — including monoclonal antibodies, peptides, proteins, gene therapies, and other large biologics — to the brain, with the potential to expand treatment options for diseases such as Alzheimer's, Parkinson's, Huntington's, amyotrophic lateral sclerosis (搜索) (ALS), and other neurological disorders.
"The acquisition of our brain delivery platform by a global pharmaceutical leader marks a major milestone for Sironax (搜索) and strongly validates our science, proprietary technology, and the expertise of our multidisciplinary R&D team," said Dr. Shefali Agarwal, President and CEO of Sironax. "This achievement comes at a pivotal time as we advance our clinical-stage pipeline and accelerate the development of promising new therapies. The proceeds from this transaction strengthen our ability to execute our strategy and continue our mission of bringing transformative medicines to patients."
Three Clinical-Stage Programs Advance
Sironax (搜索) currently has three programs in Phase 1b/2 with first- or potentially best-in-class molecules, which the company intends to advance alongside multiple early-stage candidates using the purchase proceeds.
SIR2501 is a first-in-class allosteric inhibitor of SARM1 (搜索) being developed to prevent neuroaxonal damage in diseases such as ALS and chemotherapy-induced peripheral neuropathy (搜索), for which it was granted Fast Track designation by the FDA. SIR4156 is described as an allosteric and globally first-in-class NAMPT (搜索) activator for metabolic dysfunction. SIR9900 is a highly selective, brain-penetrant allosteric RIPK1 (搜索) inhibitor in development as a potential treatment for inflammatory and immunological diseases.
Company Profile
Headquartered in Waltham, Massachusetts, Sironax (搜索) is a global clinical-stage biotechnology company developing therapies for neurodegenerative, inflammatory and immunologic, metabolic, and rare diseases. The company has built its pipeline by targeting contributors of aging: degeneration, metabolic dysfunction, and inflammation. Sironax was named to the 2025 Endpoints 11 list of the most promising biotech startups.
The company noted that its forward-looking statements regarding its pipeline, clinical plans, and use of proceeds are subject to risks and uncertainties, and that actual outcomes may differ based on technical, regulatory, and market factors.